Method of restoring the incretin effect
AssigneeNeurendo Pharma, LLC
InventorAnton H. Clemens
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of treating metabolic syndrome, Type 2 diabetes mellitus, atherogenic dyslipidemia and/or obesity. The present invention also relates to methods of restoring the incretin effect, to restoring physiologic control of glucagon levels, to restoring first-phase insulin secretion, and to restoring the physiologic glucose-dependent insulin secretion. The methods of the present invention comprise administration of a selective κ-receptor antagonist, such as guanidinylated naltrindole (GNTI), or pharmaceutically acceptable derivatives thereof to a subject in need thereof.
Claims11
1-55. (canceled)
A method of treating atherogenic dyslipidemia, comprising administering to a subject a therapeutically effective amount of a selective kappa-receptor antagonist, or a pharmaceutically acceptable derivative thereof.
65-77. (canceled)
Dependencies are inferred from the claim text.